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a  b  s  t  r  a  c  t
Background:  CXCR4  is a  chemokine  receptor  with  multiple  effects  on  the  immune  system,  upregulated
in  patients  with  SLE,  and  correlated  with  disease  severity.
Objective:  This  study  has  investigated  whether  the  levels  of  CXCR4  expressed  on leucocyte  subsets  in
lupus  patients  are correlated  with  the  efﬁcacy  and  the  safety  of  the  inﬂuenza  vaccine.
Methods:  Twenty-seven  patients  were  vaccinated  and  vaccine  immunogenicity  and  tolerance  were  eval-
uated.  CXCR4  was  assayed  on  leucocyte  subsets  and  correlated  with  clinical  and  immunological  signs of
diseases  activity.
Results: A  signiﬁcant  increase  in  the  titres  of antibodies  to  the  three  viral  strains  was  observed  along  with
trends  towards  an  increased  vaccine  efﬁcacy  in  patients  with  quiescent  disease  vs  patients  with  active
disease.  Recent  ﬂu vaccine  history  and,  to  a lesser  extent,  immunosuppressive  treatment  may  inﬂuence
vaccine immunogenicity.  Inﬂuenza  immunization  was  not  associated  with  clinical  side-effects  or  clinical
lupus ﬂare  but  with  an  increase  in rheumatoid  factor  levels.  Our  study  also  conﬁrms  the correlation  of
CXCR4  expression  with  biological  autoimmunity  as shown  by  the  correlation  between  the  percentage  of
CXCR4-positive  T cells  and  the  ANA  titres  at  D0, and  the  reverse  correlation  between  CXCR4  expression
and vaccine  immunogenicity  as  demonstrated  by  the  higher  percentage  of CXCR4-positive  T cells  at  D0
and D30  in  non-responders  vs  responders.
Conclusion:  Altogether,  our study  conﬁrms  the  efﬁcacy  and  the  safety  of  ﬂu  vaccine  in SLE patients,
highlights  the  role  of  CXCR4  as  a  surrogate  marker  for  autoimmunity  in lupus  and  shows  that  CXCR4
expression  on  T cells  is  predictive  of  vaccine  efﬁcacy  in  SLE  patients.∗ Corresponding author at: Laboratoire d’immunologie, Faculté de Médecine Paris Desc
E-mail  address: frederic.batteux@cch.aphp.fr (F. Batteux).
1 The two  authors contributed equally to this work.
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. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease
haracterized by the loss of tolerance to a variety of autoantigens,
he overactivation of B cells and a high production of immunoglobu-
ins, in particular autoantibodies [1]. The renal manifestation of SLE,
ermed lupus nephritis, occurs in approximately 50% of patients
2], and is the leading cause of morbidity and mortality [3]. CXCR4
CD186) is a membrane receptor coupled to a G-protein that exerts
any functions in the immune system. Studies of mice carrying a
argeted disruption of the CXCR4 gene have revealed a crucial role
n haematopoiesis, B cell lymphopoiesis, myelopoiesis, germinal
entre organization, and maintenance of the stem cell pool in the
one marrow [4,5]. Moreover, the role of the CXCR4/CXCL12 axis
n murine lupus nephritis has been evidenced recently [6]. It has
een clearly shown that CXCR4 is overexpressed in T and B cells in
ll murine models of lupus, including strains harbouring lupus sus-
eptibility loci from the NZB/NZW and BXSB mouse models, as well
s MRL.lpr, suggesting that CXCR4 overexpression is a generalized
eature of lupus.
The initial data have been strengthened by a clinical trial in
umans. In patients hospitalized for severe SLE with nephritis
nd/or neurological involvement, a similar dysregulation of the
XCR4/CXCL12 axis was observed [7], and CXCR4 expression on
 and T cells correlated positively with SLEDAI.
The role of CXCR4 in the formation and maintenance of germinal
entres and the severe hypogammaglobulinemia observed in the
HIM syndrome, suggest that CXCR4 plays a role in the control
f humoral response. In SLE, CD4 T cells express CXCR4 but fail to
igrate along gradients of SDF-1 because CXCR4 signalling through
he G-protein cascade is deregulated. This deregulation limits the
ccess of T lymphocytes to the germinal centres where they are
equired for B-cell help [8]. However, the abnormal upregulation
f CXCR4 in lupus patients probably overcomes the deﬁciency in
XCR4 signalling.
Infections are frequent cause of death in SLE patients, account-
ng for up to 20–35% of all deaths [9]. In one study, infection was the
rimary cause of death in 32% of 124 deaths and it contributed to
control the activity of the disease. Infections of the respiratory
tract are most common [9], leading to the recommendation of
annual inﬂuenza vaccination in patients with chronic diseases and
those with immunodeﬁciency. More than 14 published studies
have evaluated seasonal inﬂuenza vaccine in patients with lupus.
Whereas several studies have shown normal efﬁcacy [11–14], oth-
ers have suggested a reduced antibody response compared with
that in healthy adults [15–22]. Moreover, if seasonal inﬂuenza vac-
cine in patients with lupus has been shown in many studies to be
well tolerated and to result in no change in disease activity in SLE
[11–22], it may  trigger the short-term generation of autoantibodies
in some patients [15,21]. The factors that may  be responsible for this
autoantibody production are not clear but we  believe that the risk
exists of inducing autoimmunity in SLE patients with an elevated
level of CXCR4. Indeed, the hyperexpression of CXCR4 in T cells
may  drive these cells to the germinal centre where they may  trig-
ger B cell activation and thus facilitate the development of anti-viral
immune response and possibly autoimmunity.
The aim of this study was to determine whether the levels of
CXCR4 expressed on leucocyte subsets in lupus patients are corre-
lated with vaccine efﬁcacy and with the risk of developing clinical
and biological signs of autoimmunity following the administration
of the inﬂuenza vaccine.
2. Materials and methods
2.1. Ethics
All participants gave written informed consent before enroll-
ment. The protocol was  conducted in accordance with the
Declaration of Helsinki and French law for biomedical research,
and was approved by the “Ile-de-France 3” Ethics Committee (Paris,
France), on October 2, 2009; no. 09-12075.
The study is registered at Clinicaltrials.gov under #
NCT01072734.
2.2. Study design and participants
eath in other 10% of the patients [10]. In patients with SLE, the risk
f infection is related to intrinsic changes in immune responses,
ut also to the use of immunosuppressive drugs (corticosteroids,
MARDs and biotherapies (rituximab, abatacept)), needed toThis was  a prospective, single arm clinical trial performed in
ﬁve centres in France. Patients were eligible to participate if they
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lassiﬁcation of systemic lupus erythematosus (SLE). Main exclu-
ion criteria were pregnancy, hepatitis B virus, hepatitis C and
IV infection, cancer, cirrhosis, hypersensitivity to active sub-
tances, eggs or one of the vaccine components, acute severe illness
ithin the last 30 days, treatment by anti-CD20 mAb  ongoing
r stopped for less than 1 year or administration of blood prod-
cts such as immunoglobulins within the last 90 days before the
ime of vaccination. Immunosuppressive treatment was  recorded.
mong the 27 patients included, one did not receive immunosup-
ressive drugs, ﬁve received hydroxychloroquine, six were treated
ith corticosteroids only and 15 received imurel, cellcept, neoral,
ethotrexate or endoxan.
.3. Vaccine
Patients received one injection of the 2009–2010 seasonal
rivalent inactivated inﬂuenza vaccine (Mutagrip®, Sanoﬁ Pas-
eur Paris, France). The vaccine contained the three virus-like
trains: A/Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2)
nd B/Brisbane/60/2008, and was administered intra-muscularly
n the deltoid region (0.5 ml  containing at least 15 g of haemag-
lutinin per strain). For patients treated with anticoagulant, the
accine was administered subcutaneously in the deltoid region at
he same dose.
.4. Outcomes and follow-up
Blood samples were planned for assessment of
aemagglutination-inhibition (HI) antibodies (Abs), antinu-
lear antibodies, complement and interferon activities at day 0
efore vaccination, and at days 7 and 30 post-vaccination. Standard
iochemical and blood cell tests were planned at days 0, 7, and 30.
LE activity was determined at D0 before vaccination and at D30
ost-vaccination using the SLE Disease Activity Index (SLEDAI).
.4.1. Assessment of adverse events
Local and general reactions were collected during the ﬁrst
0 min  after vaccination at the hospital. Patients were then pro-
ided with diary cards to record the occurrence and severity of
olicited local reaction at the site of injection (pain, erythema,
nduration, nodule, and/or oedema), solicited general reactions
fever (at least 37.5 ◦C), headache, malaise, nausea, diarrhoea, rash,
yalgia and/or arthralgia) and unsolicited adverse events during
he 30 days following vaccine injection. Adverse events were cod-
ﬁed for their relationship to the study product (none, possibly,
robably or certainly related) and assigned a severity grade (mild
grade 1) with no limitation of activities and no medical inter-
ention; moderate (grade 2) with mild-to-moderate limitation of
ctivities and no or minimal medical intervention; severe (grade
) with marked limitation of activities and medical intervention
equired; and potentially life-threatening (grade 4)). Physicians
raded severity, using self monitoring diary cards ﬁlled by the
atients.
.4.2. Laboratory assays
.4.2.1. Serum autoantibody assays. Antinuclear Abs (ANA) were
etected using the IFI Hep-2 assay (Bioadvance, Bussy Saint Martin,
rance). Sera were considered positive when the titre was  higher
han 1:80. The anti-dsDNA AAbs detection was performed by ELISA
sing the ETI-dsDNA kit (Diasorin, Antony, France) and using the
ova Lite Crithidia Luciliae assay (Menarini, Rungis, France). Anti-
o, -La, -Sm, and -nRNP Abs were tested by standard ELISA using the
LISA ENA proﬁle plus/12 (Bioadvance). Rheumatoid factors were
ested by ELISA using the FR Lisa IgM kit from BMD (Marne la Vallée,
rance). Serum Anti-Neutrophil Cytoplasmic Abs were detected1 (2013) 3492– 3501
by indirect immunoﬂuorescence using ethanol-ﬁxed granulocytes
from Bioadvance. Sera were considered positive when the titre was
higher than 1:20. All the industrial kits were used according to the
manufacturers’ recommendations.
2.4.2.2. Complement assays. Freshly drawn EDTA plasma was
obtained from patients at different time points. Measurements of
CH50 activity were performed as previously described [23]. Results
of haemolytic assays were expressed as percentages of mean values
obtained with reference plasma prepared from 100 healthy blood
donors (normal range, 100 ± 30%). Plasma concentrations of C3 and
C4 fractions were determined by nephelometry (Beckman, Gagny,
France). Normal concentrations ranged between 0.85 ± 0.20 and
0.24 ± 0.12 g/L for C3 and C4, respectively.
2.4.2.3. Serum IFN  ˛ activity. Serum IFN levels in SLE patients
were measured using an antiviral cytopathic bioassay as previously
described [24,25]. This assay is based on the antiviral activity of
human IFN in Madin–Darby bovine kidney (MDBK) cells in the
presence of vesicular stomatitis virus (VSV), Indiana strain. Two-
fold dilutions of SLE sera were added to 20,000 MDBK cells/well
in minimal essential medium (MEM)/10% foetal bovine serum.
After overnight incubation at 37 ◦C, plates were washed with MEM,
and VSV (at a multiplicity of infection of 0.1) was added to each
well. After overnight incubation at 37 ◦C, cytopathic effects were
scored under the microscope. Dilutions of a reference human IFN
standardized by the National Institute of Health reference (Ga 023-
902-530), was included to each titration. Serum IFN titre in IU/ml
was  deﬁned as the reciprocal of the highest dilution that resulted
in the protection of 50% of cells.
2.4.2.4. Haemagglutination inhibition assay (HIA). The inﬂuenza
virus antigens used in this study were the A/Brisbane/59/2007
H1N1, the A/Brisbane/10/2007 H3N2 and the B/Brisbane/60/2008
supplied by Sanoﬁ Pasteur. Virus concentrations were previously
determined by haemagglutinin antigen titration. The immune
responses to H1N1, H3N2, and inﬂuenza B strains of the seasonal
inﬂuenza vaccine were evaluated by determining the levels of
Abs by HIA after removing the naturally occurring non-speciﬁc
inhibitors from the sera as previously described [26]. Brieﬂy,
samples were serially diluted two-fold into U-bottom 96-well
microtitre plates. An equal volume of virus suspension, adjusted
to approximately four haemagglutinin antigen units per 50 l,
was  added to each well. The plates were covered and incu-
bated at room temperature for 30 min  followed by the addition
of freshly prepared 1% human erythrocytes in phosphate buffered
saline solution. The plates were mixed by agitation, covered, and
allowed to set for an hour at 4 ◦C. The titre of haemagglutination-
inhibiting Abs was  deﬁned as the reciprocal of the highest serum
dilution that completely inhibited viral haemagglutination. Posi-
tive and negative controls were included on each plate. Samples
with haemagglutination-inhibiting Ab titres ≥1:40 were consid-
ered positive.
2.4.2.5. Flow cytometry and antibodies. Whole blood was  uptake
in speciﬁc Cyto-Chex BCT tubes (Streck, Omaha, USA). Samples
were stored in Cyto-Chex BCT for 1–7 days prior to ﬂow cytometry
immunophenotyping. The following Abs to human antigens were
used for ﬂow cytometry analyses: mouse anti-human IgM (PE;
Beckman Coulter), mouse anti-human IgD (FITC; Beckman Coul-
ter), mouse anti-human CD4 (PE-Cy7; Beckman Coulter), mouse
anti-human CD5 (PE-Cy7; Beckman Coulter), mouse anti-human
CD8 (APC-Cy7; BD Biosciences), mouse anti-human CD15 (FITC;
Beckman Coulter), mouse anti-human CD21 (APC; Beckman Coul-
ter), mouse anti-human CD24 (PE-Cy5; Beckman Coulter), mouse
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APC-Alexa750; Invitrogen), mouse anti-human CD38 (PE-Cy5;
eckman Coulter), mouse anti-human CD56 (PE-Cy5; Beckman
oulter), mouse anti-human CD184/CXCR4 (APC; BD Biosciences),
ouse anti-human CD14 (Paciﬁc Orange; Invitrogen), mouse anti-
uman CD3 (Paciﬁc Blue; DakoCytomation), mouse anti-human
19 (Paciﬁc Blue; DakoCytomation). Immunophenotyping was
ealized in three different panels. The ﬁrst panel comprised CD15-
ITC, CD25-PE, CD56-PE-Cy7, CXCR4-APC, CD8-APC-Cy7, CD3-Pac
lue and CD14-Pac Orange. Panel 2 comprises IgD-FITC, IgM-PE,
D38-PE-Cy5, CD5-PE-Cy7, CXCR4-APC, CD27-APC-Alexa750 and
D19-Pac Blue. Panel 3 comprises IgD-FITC, IgM-PE, CD24E-Cy5,
D23-PE-Alexa700 CD21-APC, CD27-APC-Alexa750 and CD19-Pac
lue. Red blood cells were lysed after staining using Versalyse
uffer (Beckman Coulter). Fluorescence was normalized using
mmunobright (Beckman Coulter). Absolute numbers of cells were
alculated using ﬂowcount ﬂuorospheres (Beckman Coulter). At
east 1 × 106 cells were acquired in the live gate, as deﬁned by size
nd granularity. Expression of cell surface markers was determined
y ﬂow cytometry and data were analysed using FACSDiva soft-
are (BD Biosciences). B cell populations were deﬁned as follows:
aive B cells (CD19+/CD27−), mature B cells (CD19+/CD27+),
emory B cells or plasmocytes (CD19+/CD27hi/CD38+),
1 cells (CD19+/CD5+), B2 cells (CD19+/CD5), transitional
1 B cells (CD19+/CD23−/IgMhi/IgDlo/CD21lo/CD24hi), T2 B
ells (CD19+/CD23hi/IgMhi/IgDhi/CD21hi/CD24hi), T3 B cells
CD19+/CD23hi/IgMhi).
.5. Statistical analysis
Each subgroup of patients had the haemagglutination inhibition
eometric mean titres (GMT) calculated prior to vaccination, then
 and 30 days after vaccination and compared using a two-sided
tudent’s t test with an  ˛ level of 0.05. The percentage of respon-
er and non-responder patients for each inﬂuenza virus antigens
as also calculated. Area of positive response is deﬁned as a two-
old increase in antibody titres between D0 and D30. The rates of
eroconversion were compared using Fisher’s exact test. For other
iological parameters, statistical analysis was performed using
wo-sided Student’s t test for unpaired data or regression analy-
is with Spearman’s test. A P value less than 0.05 was considered
igniﬁcant. For immunosuppressive treatments, the population
as divided into three groups according to treatment: group A:
ntreated patients or patients treated with hydroxychloroquine;
Fig. 1. Study ﬂow1 (2013) 3492– 3501 3495
group B: patients treated with hydroxychloroquine and/or corti-
costeroids; group C: patients receiving immunosuppressive drugs




From September 29, 2009 to November 5, 2009, 28 SLE patients
were screened, among whom 27 were vaccinated between October
7 and December 3 (Fig. 1). All but one were women. One patient
was  found HbsAg positive and excluded from the study. The demo-
graphic proﬁles and the clinical characteristics of the patients are
described in Table 1. One patient did not receive any drug, ﬁve
received hydroxychloroquine, six were treated with corticosteroids
only and 15 received immunosuppressive drugs. No change in the
dose or type of drug occurred during 30 days of the study. Seven
patients had a history of inﬂuenza immunization in the past 3 years.
3.2. Vaccine immunogenicity
Considering the whole population of patients studied, a signiﬁ-
cant increase in GMT  titres was observed for the three viral strains
both 7 and 30 days after vaccination (Table 2). For H1N1 strain GMT
titres increased from 45 at baseline to 118 at D7 (P = 0.012) and 265
at D30 (P = 4.3 × 10−5); for H3N2 strain from 41 at baseline to 52
at D7 (P = 0.009) and 60 at D30 (P = 0.005): for B strain from 79 at
baseline to 146 at D7 (P = 0.012) and 200 at D30  (P = 0.001) (Table 1).
The percentage of responders was  55.5% to H1N1 (15/27), 18.5% to
H3N2 (5/27) and 55.5% to inﬂuenza B (15/27).
3.3. Consequences of disease activity on vaccine immunogenicity
The highest GMT  increase for the three antigenic speciﬁcities
was  observed in patients with a SLEDAI at 0 but no correlation
was  observed between the SLEDAI and the immunogenicity of the
inﬂuenza vaccine whatever the antigenic speciﬁcity considered.
In addition, if the SLE population is distributed into three groups
according to the SLEDAI (≤0; 1–4 and >4), no signiﬁcant differences
are observed between groups in terms of vaccine immunogenic-
ity. However, if we compare responders and non-responders
patients in terms of disease activity, H1N1 responders had
 diagram.
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Table 1
Demographic proﬁles and clinical characteristics of the 27 patients included in the study.
SLEDAI = 0 (N = 5) SLEDAI 1 à 4 (N = 17) SLEDAI > 4 (N = 5) Total (N = 27)
SLEDAI score
N (%) 5 (18.5%) 17 (63.0%) 5 (18.5%) 27 (100.0%)
Mean (SD) 0.0 (0.0) 3.1 (1.0) 10.6 (3.4) 3.9 (3.8)
Median (Min–Max) 0.0 (0.0–0.0) 4.0 (2.0–4.0) 9.0 (8.0–16) 4.0 (0.0–16)
Age  (years)
N 5 17 5 27
Mean  (SD) 47.0 (6.3) 44.1 (10.8) 42.6 (14.3) 44.4 (10.6)
Median (Min–Max) 45.0 (40–57) 42.0 (34–74) 41.0 (25–58) 42.0 (25–74)
Sex
N  5 17 5 27
Men  0 (0.0%) 1 (5.9%) 0 (0.0%) 1 (3.7%)
Women  5 (100.0%) 16 (94.1%) 5 (100.0%) 26 (96.3%)
BMI  (kg/m2)
N  5 16 5 26
Mean  (SD) 26.8 (7.5) 24.8 (5.1) 23.9 (5.8) 25.0 (5.6)
Median (Min–Max) 25.2 (21–39) 22.5 (19–35) 21.0 (19–33) 22.5 (19–39)
Delay  between disease onset and inclusion (year)
N 5 17 5 27
Mean  (SD) 15.8 (11.7) 11.5 (8.1) 9.8 (12.9) 12.0 (9.5)
Median (Min–Max) 10.0 (4.0–32) 10.0 (1.0–32) 6.0 (1.0–32) 9.0 (1.0–32)
Number of patients with Flu vaccine history (n): 1 (20.0%) 5 (29.4%) 1 (20.0%) 7 (25.9%)
In  the vaccinated patients, history for the last three vaccination campaign
2008–2009 (x/%) 1 (100.0%) 4 (80.0%) 1 (100.0%) 6 (85.7%)
2007–2008 1 (100.0%) 5 (100.0%) 1 (100.0%) 7 (100.0%)
2006–2007 1 (100.0%) 3 (60.0%) 0 (0.0%) 4 (57.1%)
Immunosuppressive drugs (n/%)
Class A 2 (40.0%) 11 (64.7%) 4 (80.0%) 17 (63.0%)
Class  B 4 (80.0%) 12 (70.6%) 3 (60.0%) 19 (70.4%)
Class  C 5 (100.0%) 8 (47.1%) 2 (40.0%) 15 (55.6%)
Anti-platelet agent (n/%) 1 (20.0%) 5 (29.4%) 1 (20.0%) 7 (25.9%)
Anticoagulants (n/%) 1 (20.0%) 6 (35.3%) 1 (20.0%) 8 (29.6%)
NSAID  (n/%) 0 (0.0%) 1 (5.9%) 1 (20.0%) 2 (7.4%)

















eOthers  (n/%) 5 (100.0%) 
ower levels of antinuclear Abs than non-responders: 1780 ± 676
s 4749 ± 1296 prior vaccination (P = 0.038) and 1885 ± 662 vs
085 ± 1440 (P = 0.037) at D30 post-vaccination [data not shown].
owever, H1N1 and H3N2 responders and non-responders did
ot differ in terms of SLEDAI and of anti-dsDNA Abs, rheumatoid
actors, anti-ENA Abs and complement testing. Inﬂuenza B respon-
ers had lower levels of antinuclear Abs than non-responders at
0 (2677 ± 837 vs 3525 ± 1297), but this difference did not reach
igniﬁcance. Inﬂuenza B responders and non-responders did not
igniﬁcantly differ in terms of SLEDAI, the presence of anti-dsDNA
bs, rheumatoid factors, anti-ENA Abs and complement testing.
ltogether, those results indicate a trend towards a higher efﬁ-
acy of the vaccination in patients with quiescent diseases than
n patients with active disease.
able 2
nti-inﬂuenza antibodies prior to-, at D7 and D30 post-vaccination. Results are
xpressed as GMT.
SLEDAI = 0 SLEDAI = 1–4 SLEDAI > 4 All patients
H1N1
D0 50 ± 62 51 ± 60 17 ± 5 45 ± 55
D7  202 ± 254 100 ± 108 96 ± 99 118 ± 141
D30 390 ± 257 237 ± 221 234 ± 257 265 ± 233
H3N2
D0  52 ± 27 35 ± 18 48 ± 11 41 ± 20
D7  56 ± 17 44 ± 21 72 ± 11 52 ± 21
D30 96 ± 59 48 ± 28 60 ± 18 60 ± 38
Inﬂuenza B
D0 58 ± 36 92 ± 105 56 ± 44 79 ± 87
D7  128 ± 111 149 ± 175 154 ± 118 146 ± 152
D30 256 ± 222 161 ± 166 248 ± 237 200 ± 18715 (88.2%) 4 (80.0%) 24 (88.9%)
3.4. Consequences of inﬂuenza vaccine history on vaccine
immunogenicity
The levels of anti-H1N1 and anti-inﬂuenza B but not of anti-
H3N2 Abs were higher at D0 in patients with previous inﬂuenza
vaccination than in patients with no history of previous ﬂu
immunization (P = 0.022 for H1N1; P = NS for H3N2; P = 0.0057 for
inﬂuenza B) [data not shown]. However, in the seven patients with a
history of inﬂuenza vaccination, no signiﬁcant increase in the mean
titres of Abs was observed and only one of them was responder to
the single inﬂuenza B strain. By contrast, in the 21 patients without
previous inﬂuenza vaccination, a signiﬁcant increase in the titres of
the Abs to the three viral strains of vaccine was observed at D30 vs
D0 for H1N1 (P = 1.3 × 10−4), for H3N2 (P = 0.010) and for inﬂuenza
B (P = 0.0043).
Therefore, if we only consider those 21 patients without
inﬂuenza immunization history, the percentage of responders
increased to 66.6% for H1N1 (14/21), to 23.8% for H3N2 (5/21)
and to 71.4% for inﬂuenza B (15/21). Although this increase did
not reach signiﬁcance, H1N1 responders had lower levels of ANAs
than non-responders (1900 ± 717 vs 4103 ± 1579 prior vaccina-
tion and 2013 ± 698 vs 4946 ± 1827 at D30 post-vaccination), they
had lower levels of anti-histone IgG Abs than non-responders
(42.8 ± 12.7 vs 178.6 ± 84.4, prior vaccination), they had lower lev-
els of CH50 than non-responders (54.5 ± 11.3 vs 74.1 ± 8.4, prior
vaccination), they had lower levels of IFN than non-responders
(2.4 ± 0.8 vs 5.3 ± 3.3, prior vaccination) and, ﬁnally, they had a
lower SLEDAI than non-responders (3.64 ± 0.97 vs 5.71 ± 1.92, prior
vaccination). Thus, a history of inﬂuenza vaccine within the 3 years
prior to re-vaccination clearly inﬂuenced vaccine immunogenicity.
On the other hand, in patients with no previous ﬂu immunization,
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Table 3
Biological signs of autoimmunity prior to- and D30 post-inﬂuenza vaccination. Results are expressed as ANA titres, IU anti-dsDNA IgG Abs/ml, AU anti-Histone IgG and IgM
Abs/ml,  IU FR/ml, % CH50, g C3 and C4/l and IU IFN/ml.



















































eDay 0 3036 ± 3670 109 ± 172 72 ± 131 
Day  30 3239 ± 3924 120 ± 211 70 ± 132 
P  NS NS NS 
he trend towards a higher vaccine efﬁcacy in patients with quies-
ent diseases than in patients with active disease is conﬁrmed.
.5. Consequences of immunosuppressive treatment on vaccine
mmunogenicity
Differences were observed in haemagglutination-inhibiting Ab
itres according to the drug regimen of the patients. A signiﬁcant
ncrease in the titres of the Abs to H1N1 at D30 was observed
n group A (patients untreated or treated with hydroxychloro-
uine, P = 0.012), group B (patients treated with corticosteroids
nly, P = 0.063) and group C (patients treated with other immuno-
uppressive drugs, P = 0.012). No signiﬁcant increase in anti-H3N2
bs titres was observed. A signiﬁcant increase in anti-inﬂuenza B
bs titres at D30 was observed in group A, only (P = 0.045) [data
ot shown]. Thus, corticosteroids (group B) and immunosuppress-
ve drugs (group C) only exert a slight negative effect on vaccine
mmunogenicity of inﬂuenza B vaccine.
.6. Vaccine safety
No local and/or systemic reactions were observed during the
rst 30 min  post-vaccination. During the 30 days of the follow-
p, 14 patients presented at least one local reaction: erythema
n = 12), pain/discomfort (n = 5), induration (n = 3), nodule (n = 2),
aematoma (n = 1), oedema (n = 3) and pruritus (n = 1). Fifteen
atients reported at least one systemic adverse event: myalgia
n = 8), headache (n = 5), fever (n = 1), nausea (n = 1), diarrhoea
n = 2), rhinitis or bronchitis (n = 4), arthritis (n = 1), cutaneous erup-
ion (n = 2), febrile sensation (n = 1) and metrorrhagia (n = 1). All
esolved without sequelae. No serious adverse event was reported
uring the 30 days of the study.
The mean SLEDAI was 3.9 ± 3.8 at D0 and 3.3 ± 3.7 at D30 post-
accination. The SLEDAI was of 0 for ﬁve patients, between 1 and 4
or 17 patients and higher than 4 for ﬁve patients. No modiﬁcation
as observed regarding the number of patients in each group at
30 following vaccination [data not shown]. The SLEDAI decreases
−1.58 ± 0.54) between D0 and D30 in patients with no adverse
vents but increases (0.20 ± 0.63) in patients with adverse events
P = 0.043). No biological assays or their variation between D0 and
30 were predictive of occurrence of adverse events.
No elevation in antinuclear Abs was observed during the study;
he mean antinuclear antibody titre was 3036.2 ± 3670.2 at D0 vs
239.2 ± 3924.5 (P = NS) at D30. IgG anti-dsDNA Abs levels were
09.0 ± 171.9 A.U vs 120.4 ± 210.9 A.U (P = NS) at D30 (Table 3).
ifteen patients were positive for anti-ENA Abs at D0 and 14
ere positive at D30 (P = NS). Two patients were positive for anti-
eutrophil cytoplasmic Abs at D0 and four were positive at D30
P = NS). IgG anti-histone Abs levels were 72.2 ± 131.1 AU at D0 vs
0.4 ± 131.7 AU at D30 (P = NS). IgM anti-histone Abs levels were
7.4 ± 96.8 AU at D0 vs 64.8 ± 96.9 AU at D30 (P = NS). Rheumatoid
actor is the only autoantibody signiﬁcantly modiﬁed by the vaccine
ince its levels increased from 23.0 ± 20.3 AU at D0 to 27.7 ± 27.4 AU
t D30 (P = 0.0169).
The haemolytic complement CH50 activity was  72.2% ± 34.4 at
0 and increased signiﬁcantly at 91.0% ± 29.2 (P = 0.0050). How-
ver, no signiﬁcant differences were observed for the C3 fraction: 97 23 ± 20 72 ± 34 0.9 ± 0.2 0.2 ± 0.1 3.0 ± 5.0
 97 28 ± 27 91 ± 29 0.9 ± 0.2 0.2 ± 0.1 2.4 ± 2.8
0.017 0.005 NS NS NS
0.9 g/l ± 0.2 at D0 vs 0.9 g/l ± 0.2 at D30 (P = 0.2802) or for the C4
fraction as well: 0.2 g/l ± 0.1 at D0 vs 0.2 g/l ± 0.1 at D30 (P = 0.2297).
Altogether, those data conﬁrm the safety of inﬂuenza vaccine
even in patients with active disease even if some immunological
parameters can be impacted by the immunization.
3.7. Expression of CXCR4 on various leucocyte subsets prior to
vaccination, at D7 and D30 post-vaccination
If the results of our study conﬁrm the efﬁcacy and the safety
of inﬂuenza vaccine in SLE patients, our goal was  to determine
whether levels of CXCR4 expressed on leucocyte subsets in lupus
patients are correlated with the risk of developing clinical and/or
biological signs of autoimmunity following the administration of
the inﬂuenza vaccine. Therefore, we  ﬁrst evaluated the expres-
sion of CXCR4 on various leucocyte subsets prior to vaccination,
then at D7 and D30 post-vaccination (Fig. 2). The mean percent-
age of CXCR4 on CD3+T cells was 14.9% ± 13.6 at D0, 12.5% ± 11.3
at D7 and 10.5% ± 9.6 at D30 (P = NS). The same was  observed
on both CD4+ and CD8+ T cells since the percentage of CXCR4
on CD4+ T cells was  23.0% ± 17.7 at D0, 17.4% ± 15.4 at D7 and
17.4% ± 15.3 at D30 (P = NS). The percentages of CXCR4 on CD8+
T cells were 23.3% ± 14.9 at D0, 20.5% ± 15.5 at D7 and 17.8% ± 12.6
at D30 (P = NS). The decrease in the mean percentage of CXCR4 on
T cell subsets was  also associated with a decrease in the mean
ﬂuorescence intensity (MFI) of CXCR4 expressed on those cells.
However, the decrease in MFI  did not reach statistical signiﬁcance
[data not shown]. The mean percentage of CXCR4 on CD15+ cells
signiﬁcantly decreased from 24.5% ± 23.7 at D0 to 17.2% ± 16.3
(P = 0.08) at D7 and 10.4% ± 14.6 at D30 (P = 0.01), whereas the MFI
of CXCR4 on those cells was not modiﬁed between D0 and D30.
The mean percentage of CXCR4 in CD14+ cells was  also signiﬁ-
cantly decreased from 34.4% ± 32.0 at D0 to 23.7% ± 25.6 (P = 0.11)
at D7 and 9.0% ± 13.5 at D30 (P = 0.0003). As on CD15+ cells, the
MFI  of CXCR4 on CD14+ cells was  not modiﬁed between D0  and
D30. No signiﬁcant alteration was observed in the expression of
CXCR4 on total CD19+ B cells, on various B cell subsets such
as marginal zone CD19+CD5−IgD+CD27+ B cells, switch memory
CD19+CD5−IgD−CD27+ B cells or CD19+CD5−CD27+CD38+ plasma
cells. Only naive CD19+CD5−IgD + CD27− B cells expressed signiﬁ-
cantly lower levels of CXCR4 at D30: 60.7% ± 19.1 at D0, 53.8% ± 22.6
(P = 0.16) at D7, and 45.9% ± 24.2 at D30 post-vaccination (P = 0.02),
while the MFI  of CXCR4 on those cells was not modiﬁed between
D0 and D30. Therefore, the inﬂuenza vaccine did not inﬂuence the
expression of CXCR4 on leucocyte subsets but the percentage of
CXCR4-positive naive B cells, neutrophils and monocytes were sig-
niﬁcantly decreased 30 days after ﬂu vaccination.
3.8. Correlation between CXCR4 expression on various leucocyte
subsets and vaccine immunogenicity
No correlation was  observed between anti-H1N1 Abs titres and
the expression of CXCR4 on leucocyte subsets either in terms of
percentages or of mean ﬂuorescence intensity. However, the per-
centages of CXCR4 CD3+ T cells and of CXCR4 CD4+ T cells at D0
were signiﬁcantly higher in H1N1 non-responders (n = 12) than in
H1N1 responders (n = 15) (P = 0.020 for CD3+ T cells and P = 0.011




























Tig. 2. Expression of CXCR4 on various leucocyte subsets. Percentages of CXCR4
acrophages, CD15+ neutrophils, CD19+ B cells, marginal zone-, naive-, switch-B
ection 2. CXCR4 expression was  determined prior to -, at D7 and D30 post-vaccina
or CD4+ T cells) (Fig. 2). The percentages of CXCR4 CD3+ T cells,
f CXCR4 CD4+ T cells and of CXCR4 CD8+ T cells at D30 were
igniﬁcantly higher in non-responders to H1N1 than in respon-
ers (P = 0.012 for CD3+ T cells and P = 0.011 for CD4+ T cells and
 = 0.025). No correlation was observed between the anti-H3N2 Abs
itres and the levels of CXCR4 expression in leucocyte subsets were
ither expressed in terms of percentages or of MFI. The levels of
XCR4 expressed at D0 or at D30 on the various cellular subsets
ested were not signiﬁcantly different between non-responders to
3N2 (n = 22) and responders (n = 5). No correlations were observed
etween anti-inﬂuenza B Abs titres and the levels of CXCR4 expres-
ion in leucocyte subsets either in terms of percentages or of MFI.
owever, the percentage of CXCR4 CD3+ T cells and of CXCR4 CD4+
 cells at D0 was signiﬁcantly higher in inﬂuenza B non-responders
n = 12) than in inﬂuenza B responders (n = 15) (P = 0.016 for CD3+
 cells and P = 0.017 for CD4+ T cells) [data not shown].
In patients with no immunization history, the percentage of
XCR4 CD3+ T cells and of CXCR4 CD4+ T cells at D0 and D30 was
igniﬁcantly higher in H1N1 non-responders (n = 7) than in H1N1
esponders (n = 14) (P = 0.025 for CD3+ T cells and P = 0.016 for CD4+
 cells at D0 and P = 0.044 for CD3+ T cells and P = 0.046 for CD4+ T
ells at D30). In addition, in those patients without immunization
istory, the percentage of CXCR4 CD3+ T cells and of CXCR4 CD4+ T
ells at D0 was signiﬁcantly higher in inﬂuenza B non-responders
n = 6) than in inﬂuenza B responders (n = 15) (P = 0.017 for CD3+
 cells and P = 0.016 for CD4+ T cells). Thus, if no correlation wasive cells were determined on CD3+, CD4+, CD8+ T cells, CD56+ NK cells, CD14+
, and plasma cells by ﬂow cytometry using the panel of antibodies described in
observed between H1N1, H3N2 or inﬂuenza B titres and the expres-
sion of CXCR4 on leucocyte subsets either in terms of percentages
or of mean ﬂuorescence intensity, the percentage of CXCR4 CD3+
T cells and of CXCR4 CD4+ T cells at D0 and D30 was  signiﬁcantly
higher in non-responders to the H1N1 and inﬂuenza B strains than
in responders.
3.9. Correlation between CXCR4 expression on various leucocyte
subsets and vaccine safety
No correlations were observed between either the mean or the
percentage of CXCR4 expression determined at D0 on the vari-
ous leucocyte subsets and the evolution of the SLEIDAI between
D0 and D30. In addition, no correlations were observed between
either the evolution of the mean or of the percentage of CXCR4
expression between D0 and D30, determined on the various leu-
cocyte subsets and the evolution of the SLEIDAI between D0  and
D30. By contrast, a positive correlation was  observed between the
basal titre of total anti-nuclear Abs and the basal expression of
CXCR4 on CD3+ T cells (P < 0.0001), on CD4+ T cells (P < 0.0008),
on CD8+ T cells (P < 0.0001) and on CD14+ monocytes (P < 0.0013).
Remarkably, a negative correlation was  observed between the basal
titre of total anti-nuclear autoantibodies and the basal expres-
sion of CXCR4 on CD19+ B cells (P < 0.0013) [data not shown].
No correlation was observed between the evolution of total anti-
nuclear Abs titres between D0 and D30 and the evolution of CXCR4
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bDnCXCR4) between D0 and D30 post-vaccination. (B) Correlation between the vari
n  CD3+, CD4+ and CD8+ T cells (delta CDnCXCR4) between D0 and D30 post-vaccin
xpression on the various leucocyte subsets. No correlation was
lso found between CXCR4 expression at D0 and the evolution of
ntinuclear Abs titres between D0 and D30. By contrast, a negative
orrelation was observed between the evolution of rheumatoid fac-
ors concentration between D0 and D30 and the basal expression of
XCR4 on CD3+ T cells (P = 0.036), on CD4+ T cells (P = 0.068) and on
D8+ T cells (P = 0.020): a low expression of CXCR4 on those subsets
as correlated with an increased concentration of rheumatoid fac-
ors between D0 and D30 (Fig. 3). Moreover, a positive correlation
as observed between the evolution of rheumatoid factors concen-
ration between D0 and D30 and the evolution of CXCR4 expression
etween D0 and D30 on CD3+ T cells (P = 0.030), on CD4+ T cells
P = 0.030) and on CD8+ T cells (P = 0.046): an increasing level of
XCR4 on those subsets was correlated with an increased concen-
ration of rheumatoid factor between D0 and D30. In conclusion,
f no correlations were observed between either the means or the
ercentages of CXCR4 expression on the various leucocyte subsets
nd the evolution of the SLEDAI between D0 and D30, a positive cor-
elation was observed between the percentage of CXCR4-positive
 cells at D0 and the basal ANA titres conﬁrming, the correlation
etween CXCR4 expression and activity of the autoimmune processn rheumatoid factor concentration (delta RF) and the variation in CXCR4 expression
.
in lupus patients. On the other hand, the inﬂuence of CXCR4 on the
autoimmune response upon inﬂuenza vaccination is suggested by
the positive correlation between the levels of CXCR4 expression on
T cells and the elevation of rheumatoid factor levels between D0
and D30.
4. Discussion
The aim of this study was to evaluate whether in lupus patients
immunized with inﬂuenza vaccine, the levels of CXCR4 expressed
on certain leucocyte subsets are correlated with vaccine efﬁcacy
and/or vaccine safety as determined by the risk of developing clin-
ical and/or biological signs of autoimmunity upon administration
of the inﬂuenza vaccine.
In the 27 patients tested, a signiﬁcant increase in the titres of
antibodies to H1N1, H3N2 and inﬂuenza B viral strains is observed
7 and 30 days post-vaccination, but the percentages of respon-
ders at day 30 are only of 55.5%, 18.5% and 55.5%, for H1N1, H3N2
and inﬂuenza B strains, respectively. Our results are in agree-
ment with previous studies since, in SLE, a diminished response
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everal times [15,23,24]. In a previous study, only 58%, 63%, and
8% of the 24 SLE patients who received the split virion, inactiv-
ted vaccine of A/Beijing/262/95 (H1N1), A/Sydney/05/97 (H3N2),
nd B/Harbin/07/94 responded to the vaccine, while more than 90%
f responses were observed in an age- and sex-matched general
opulation with similar basal protective levels and GMT  of HI Abs
15]. In another study, 56 SLE patients with quiescent disease and
8 healthy controls received an inﬂuenza vaccination. SLE patients
howed fewer seroconversions: 43% patients vs 94% controls for
/H1N1, 39% patients vs 88% controls for A/H3N2 and 41% patients
s 71% controls for B/Hong Kong [17]. It has been recently reported
hat the rate of seroprotection ranges between 62% and 73% in SLE
atients compared to 90% and 98% in the control group (P < 0.05)
21].
The clinical relevance of such a low number of responders is
till unclear. As observed by us and others, the highest increase in
b titres to the three antigenic speciﬁcities is observed in patients
ith a SLEDAI of zero, but no correlation is observed between
he SLEDAI and the immunogenicity of the inﬂuenza vaccine or
he responder/non-responder status, whatever the antigenic speci-
city. However, the weaker efﬁciency of the vaccine could be
elated to the severity of the immunological signs of autoimmunity
ince H1N1 and inﬂuenza B responders have lower levels of antinu-
lear Abs than non-responders. The trend towards a better vaccine
fﬁcacy in patients with quiescent disease is conﬁrmed when
nly naive patients are considered. Although, as already observed,
he use of immunosuppressive medication can also decrease the
umoral response, [15,17,25] we found no correlation between the
mmunosuppressive therapy and the intensity of the serological
esponse. Corticosteroids alone (group B) or immunosuppressive
rugs alone (group C) exerts only a weak effect on the immuno-
enicity of the inﬂuenza B strain.
As far as side-effects are considered, we observed no clinical
dverse effects upon vaccination and no clinical ﬂare of lupus.
ndeed, the mean SLEDAI between D0 and D30 was not signif-
cantly altered, whatever the SLEDAI at D0. A trend towards an
ncrease in autoAb levels is observed after ﬂu vaccination especially
n patients without ﬂu vaccine history but this increase is restricted
o rheumatoid factors (P = 0.0169). Haemolytic complement CH50
ctivity also increases between D0 and D30, probably reﬂecting
he systemic inﬂammatory process generated by vaccination, but
o variation in C3 and C4 fractions is observed. Nevertheless, we
hould emphasize that this study, as most previous studies pub-
ished, has been conducted during a short period (30 days), and we
annot rule out that some clinical and/or immunological event may
ave occurred later on.
Vaccinating patients suffering from autoimmune diseases has
een a subject of discussion for many years. Case reports have sug-
ested that vaccination could activate autoimmune mechanisms
nd the development of subsequent autoimmune diseases has been
eported. For instance, SLE developing following hepatitis B or
treptococcal vaccination [26,27], multiple sclerosis after hepatitis
 vaccination [28] or Guillain–Barre syndrome following inﬂuenza
accination [29] have been published. Most of those publications
ere controversial but the issue of SLE ﬂares induced by vaccines
as been a constant matter of concern. Thus, according to previous
eports, one patient (out of 20) developed a serious ﬂare of pre-
xisting nephritis following inﬂuenza vaccination [12], and another
atient (out of a series of 11 patients) displayed increased disease
ctivity [14]. On the other hand, Abu-Shakra et al. studied the lev-
ls of autoAbs in a cohort of 24 SLE patients. Inﬂuenza vaccination
nduced a transient rise in serum autoAb levels in about 10–15% of
atients that was not associated with an increase in disease activ-
ty [15]. In 55 SLE patients with quiescent disease, Holvast et al.
howed that the SLEDAI did not increase within 1 month follow-
ng inﬂuenza vaccination [17]. Although inﬂuenza vaccination in1 (2013) 3492– 3501
SLE patients may  generate autoimmune biological phenomena, no
clinical complication can be expected.
Several clinical trials have attempted to evaluate the efﬁcacy and
safety of vaccination against the pandemic H1N1 virus in patients
with SLE and other connective tissue diseases. They have con-
ﬁrmed the data previously obtained with the seasonal inﬂuenza
vaccine [21,23–25,30–33]. Our study not only conﬁrms the safety
of inﬂuenza vaccine in SLE patients, but also conﬁrms that ﬂu vac-
cine may  be less effective in SLE patients than in healthy subjects
and that it can elicit the production of autoAbs [17].
Actually, the goal of our study was  to determine whether the lev-
els of CXCR4 expressed on leucocyte subsets in lupus patients are
correlated with vaccine efﬁcacy or with the risk of developing clin-
ical and/or biological signs of autoimmunity. No correlations were
observed between the expression of CXCR4 on leucocyte subsets
and the titres of the three inﬂuenza strains. However, an increased
expression of CXCR4 on T cells along with high levels of antinuclear
Abs was observed at D0 and D30 in patients non-responders to
H1N1 and inﬂuenza B strains compared to responders. Those data
conﬁrm the association of CXCR4 expression on T cells with disease
activity and poor response to inﬂuenza vaccine. Given that high
levels of CXCR4 allow the migration of CD4 T cells to the germinal
centres and the production of antibodies [8], the strong expression
of CXCR4 on T cells is in accordance with the elevated concentra-
tions of antinuclear Abs, but not with the absence of response to
inﬂuenza vaccine. Several explanations could be proposed. First,
the severity of autoimmunity in patients could overwhelm the
immunostimulatory effects of CXCR4 on humoral immunity [34].
Second, since CXCR4 signalling is different in autoimmune and in
non-autoimmune patients, one could argue that the downstream
signalling of CXCR4 in autoimmune patients may  also be differ-
ent in auto-reactive T cells and in non-autoreactive T cells such
as anti-viral T cells [8]. These two hypotheses become plausible
if the changes in rheumatoid factor concentrations are correlated
with the basal expression of CXCR4 on T cells and with its evo-
lution between D0 and D30. No correlation is found between the
changes in CXCR4 levels on the leucocyte subsets and the evolution
of the anti-inﬂuenza antibodies titres, while a negative correla-
tion is observed between CXCR4 expression on T cells at D0 and
the elevation of rheumatoid factors between D0 and D30. Those
data show that an increased antibody production is favoured by a
remission of lupus associated with a low basal level of CXCR4 on
T cells. However, a positive correlation was  also found between
CXCR4 expression on T cells from D0 to D30 and the evolu-
tion of rheumatoid factors between D0 and D30. Thus, although
both anti-inﬂuenza antibodies and rheumatoid factors rise upon
vaccine, increased CXCR4 expression is only correlated with
increased autoantibody production, suggesting that, indeed, the
downstream signalling of CXCR4 is different in auto-reactive T cells
and in non-autoreactive T cells and that CXCR4 is more impli-
cated in the production of autoAbs than in the anti-viral immune
response.
IgM and IgG antibodies have different kinetics of production
which can explain that rheumatoid factors are the only autoAbs
modiﬁed between D0 and D30 since the other autoAbs tested gen-
erally belong to the IgG isotype. Moreover, the induction of RFs
following vaccination has been reported a long time ago [35,36].
It probably reﬂects the interaction between vaccine antibodies,
anti-idiotypic antibodies secondarily generated, and ﬁnally anti-
IgG rheumatoid factors [37].
In conclusion, our study shows a signiﬁcant increase in the
titres of Abs to the three viral strains along with a trend towards
an increase in vaccine efﬁcacy in patients with quiescent dis-
eases. A recent history of ﬂu vaccine and, to a lesser extent, an
immunosuppressive treatment tends to decrease vaccine immuno-
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linical side-effects or lupus ﬂare but some auto-immune param-
ters increase following ﬂu vaccine. Our study also conﬁrms the
orrelation between a high level of expression of CXCR4 with
iological autoimmunity and decreased vaccine immunogenic-
ty. Moreover, while inﬂuenza vaccine does not inﬂuence CXCR4
xpression on T cells, and an elevated expression of CXCR4 is asso-
iated with an increase in autoAbs but not of anti-virus antibodies.
ccordingly, inﬂuenza vaccination in patients with a quiescent SLE
isease could be recommended. Nevertheless, patients with active
LE, consequently with high CXCR4 expressions on T cells, could
e efﬁciently vaccinated but cautious need to be taken in this pop-
lation because of induction of biological autoimmunity and poor
mmunogenicity following inﬂuenza vaccination.
Hence, the determination of CXCR4 levels can be considered as
 surrogate marker of lupus autoimmunity and its increase associ-
ted with poor vaccine efﬁcacy.
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